Clinical trial
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced…
NCT00003995 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003995 |
|---|---|
| Title | Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2 |
| Official title | Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, irinotecan hydrochloride |
| Enrollment | 32 |
| Start date | Sep 1, 1999 |
| Primary completion | Mar 1, 2006 |
| First posted | Jun 25, 2004 |
| Last update posted | Feb 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: